The Complement System in Ovarian Cancer: An Underexplored Old Path

Area of Science:

• Immunology
• Oncology
• Gynecologic Oncology

Background:

• Ovarian cancer remains a leading cause of cancer death among women.
• Current treatments often lead to therapy resistance, limiting long-term patient survival.
• Immunotherapy shows limited efficacy in ovarian cancer, necessitating novel therapeutic approaches.

Purpose of the Study:

• To explore the role of the complement system in ovarian cancer immunity.
• To understand how complement activation impacts the tumor microenvironment and disease progression.
• To discuss the potential of targeting complement pathways for improved ovarian cancer treatment.

Main Methods:

• Review of current literature on innate and adaptive immunity in ovarian cancer.
• Analysis of the complement system's components (e.g., C1q, C3a, C5a) and their receptors (C3aR, C5aR1).
• Discussion of complement's role in inflammation, immunosuppression, angiogenesis, and signaling pathways within the tumor microenvironment.

Main Results:

• Complement activation within the tumor microenvironment can promote chronic inflammation and immunosuppression.
• Complement effectors like C1q, C3a, and C5a are implicated in ovarian cancer progression.
• The precise clinical implications of these complement factors require further investigation.

Conclusions:

• The complement system is a critical regulator of ovarian cancer immunity and progression.
• Understanding the interplay between ovarian cancer cells and complement is crucial for developing new therapies.
• Targeting the complement system presents a promising strategy to overcome treatment resistance and improve outcomes in ovarian cancer.